Duloxetine: a new selective and dual-acting antidepressant

Bibliography

• HIRSCHFELD RMA: History and evolution of the monamine hypothesis of depression. J. Clin. Psychiatry (2000) 61(Suppl. 6):4-6.
   PubMed Web of Science ®Google Scholar
• SCHILDKRAUT JJ: The catecholamine hypothesis of affective disorders. A review of supporting evidence. Int. J. Psychiatry (1967) 4:203-217.
   PubMedGoogle Scholar
• STAHL SM: The psychopharmacology of painful physical symptoms in depression. J. Clin. Psychiatry (2002) 63:382-383.
   PubMed Web of Science ®Google Scholar
• GRECO T, ECKERT G, KROENKE K: The outcome of physical symptoms with treatment of depression. J. Gen. Intern. Med. (2004) 19:813-818.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, HENRY J, MCDONALD G et al.: Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol. (1994) 9:47-53.
   PubMed Web of Science ®Google Scholar
• BAUER M, WHYBROW PC, ANGST J, VERSIANI M, MÖLLER HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatr. (2002) 3:5-43.
   PubMedGoogle Scholar
• BYMASTER FP, DRESHFIELD-AHMAD LJ, THELKELD PG et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol. (2001) 25:871-880.
   PubMed Web of Science ®Google Scholar
• TATSUMI M, GROSHAN K, BLAKELY RD, RICHELSON E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. (1997) 340:249-58.
   PubMed Web of Science ®Google Scholar
• KOCH S, HEMRICK-LUECKE SK, THOMPSON LK et al.: Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology (2003) 45:935-944.
   PubMed Web of Science ®Google Scholar
• JAIN R: Single-action versus dual-action antidepressants. Prim. Care Companion J. Clin. Psychiatry (2004) 6(Suppl. 1):7-11.
   PubMedGoogle Scholar
• RICHELSON E: The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacology Bulletin (2002) 36:140.
   Google Scholar
• ELI LILLY AND COMPANY: Cymbalta® (duloxetine) prescribing information. Eli Lilly and Company Indianapolis (IN), USA (2005).
   Google Scholar
• SKINNER MH, SKERJANEC A, SEGER M et al.: The effect of food and bedtime administration on duloxetine pharmacokinetics. Int. J. Clin. Pharmacol. Ther. (2000) 67:129.
   Google Scholar
• SHARMA A, GOLDBERG MJ, CERIMELE BJ: Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol. (2000) 40:161-167.
   PubMed Web of Science ®Google Scholar
• LANTZ RJ, GILLESPIE TA, RASH TJ et al.: Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Disposition (2003) 31:1142-1150.
   PubMed Web of Science ®Google Scholar
• SKINNER MH, KUAN HY, PAN A et al.: Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. (2003) 73:170-177.
   PubMed Web of Science ®Google Scholar
• SKINNER MH, KUAN H-Y, SKERJANEC A et al.: Effect of age on the pharmacokinetics of duloxetine in women. Br. J. Clin. Pharmacology (2003) 57:54-61.
   Google Scholar
• MÜLLER WE, HAEN E, FRITZE J, RÜTHER E, BAUER U, MOELLER HJ: Selektive serotonin- und noradrenalin-wiederaufnahmehemmer (SSNRI). Antidepressiva mit dualem wirkungsmechanismus. Psychopharmakotherapie (2004) 11:71-75.
   Google Scholar
• DETKE MJ, LU Y, GOLDSTEIN DJ et al.: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry. (2002) 63:308-315.
   PubMed Web of Science ®Google Scholar
• DETKE MJ, LU Y, GOLDSTEIN DJ et al.: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. (2002) 36:383-390.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, MALLINCKRODT C, LU Y, DEMITRACK MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry (2002) 63:225-231.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, LU Y, DETKE MJ et al.: Duloxetine in the treatment of depression. A double blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacology (2004) 24:389-399.
   PubMed Web of Science ®Google Scholar
• MALLINCKRODT CH, GOLDSTEIN DJ, DETKE MJ et al.: Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim. Care Companion J. Clin. Psychiatry (2003) 5:19-28.
   PubMedGoogle Scholar
• NEMEROFF CB, SCHATZBERG AF, GOLDSTEIN DJ et al.: Duloxetine for the treatment of major depressive disorder. Psychopharmacol. Bull. (2002) 36:106-132.
   PubMedGoogle Scholar
• DETKE MJ, GILABERTE I, PERAHIA DG et al.: Duloxetine versus placebo in the prevention of relapse of major depressive disorder. Eur. Psychiatry (2004) 19(Suppl. 1):214s.
   PubMedGoogle Scholar
• RASKIN J, GOLDSTEIN DJ, MALLINCKRODT CH, FERGUSON MB: Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry (2003) 64:1237-1244.
   PubMed Web of Science ®Google Scholar
• HIRSCHFELD RMA, MALLINCKRODT CH, DETKE M et al.: Early symptom response during treatment with duloxetine 60 mg QD: HAMD17 items. Presented at the 157th Annual Meeting of the American Psychiatric Association. New York, USA (1 – 6 May 2004) NR536.
   Google Scholar
• DUNNER DL, GOLDSTEIN DJ, MALLICKRODT CH et al.: Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety (2003), 18:53-61.
   PubMed Web of Science ®Google Scholar
• WOHLREICH MM, MALLINCKRODT CH, WATKIN JG, HAY DP: Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 or older: an open label study. BMC Geriatrics (2004) 4:11.
   PubMedGoogle Scholar
• THASE M, LU Y, JOLIAT M, DETKE M: Remission rates in double-blind, placebo-controlled clinical trials of duloxetine with SSRI as a comparator. Eur. Neuropsychopharmacol. (2003) (Suppl.):S259.
   Google Scholar
• SWINDLE RW, ROSENBAUM JF, MALLINCKRODT CH et al.: Efficacy of duloxetine treatment: analysis of pooled data from six placebo and SSRI-controlled clinical trials. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):P02.177.
   Web of Science ®Google Scholar
• DETKE MJ, WILTSE CG, MALLINCKRODT CH et al.: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Pharmacopsychiatry (2004) 14:457-470.
   Google Scholar
• GOLDSTEIN DJ, LU Y, DETKE MJ et al.: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics (2004) 45:17-28.
   PubMed Web of Science ®Google Scholar
• FAVA M, MALLINCKRODT CH, DETKE MJ et al.: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry (2004) 65:521-530.
   PubMed Web of Science ®Google Scholar
• WOHLREICH MM, MALLINCKRODT CH, LU Y, DETKE MJ: Efficacy of duloxetine (60 mg QD) in the treatment of painful physical symptoms in patients with major depression.Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco, USA (17 – 22 May 2003) NR438.
   Google Scholar
• IYENGAR S, WEBSTER AA, HEMRICK-LUECKE SK et al.: Efficacy of duloxetine, a potent and balanced serotonin-norepinedphrine reuptake inhibitor in persistent pain models in rats. J. Pharmacol. Exp. Ther. (2004) 311:576-684.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, LU Y, DETKE MJ et al.: Duloxetine versus placebo in patients with painful diabetic neuropathy. Pain (2005) 116:109-118.
   PubMed Web of Science ®Google Scholar
• RASKIN J, PRITCHETT Y, CHAPPELL A, D’SOUZA D, WERNICKE J: Duloxetine in the treatment of diabetic peripheral neuropathic pain – results from three clinical trials. Presented at the 158th Annual Meeting of the American Psychiatric Association. Atlanta, USA (21 – 26 May 2005) NR478.
   Google Scholar
• WERNICKE JF, LU Y, D’SOUZA DN et al.: Duloxetine at doses of 60 mg QD and 60 mg BID is effective treatment of diabetic neuropathic pain. Presented at the 157th Annual Meeting of the American Psychiatric Association. New York, USA (1 – 6 May 2004) NR437.
   Google Scholar
• ARNOLD LM, LU Y, CROFFORD LJ et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. (2004) 50:2974-2984.
   PubMed Web of Science ®Google Scholar
• WERNICKE JF, ROSEN AS, PRITCHETT YL, SOUZA DN, WESTELL DJ, ARNOLD LM: Duloxetine in the treatment of women with fibromyalgia. Presented at the 158th Annual Meeting of the American Psychiatric Association. Atlanta, USA (21 – 26 May 2005) NR860.
   Google Scholar
• GREIST J, MCNAMARA RK, MALLINCKRODT CH et al.: Incidence and duration of antidepressant -induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin. Ther. (2004) 26:1446-1455.
   PubMed Web of Science ®Google Scholar
• THASE ME, TRAN PV, WILTSE C et al.: Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. (2005) 25:132-140.
   PubMed Web of Science ®Google Scholar
• MONTEJO AL, LLORCA G, IZQUIERDO JA, ROCO-VILLADEMOROS: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J. Clin. Psychiatry (2001) 62(Suppl. 3):10-21.
   PubMed Web of Science ®Google Scholar
• DELGADO P, BRANNAN S, MALLINCKRODT C et al.: Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J. Clin. Psychiatry (2005) 66:686-692.
   PubMed Web of Science ®Google Scholar